Morning Glory Sciences– Author –
After completing graduate school, I studied at a Top tier research hospital in the U.S., where I was involved in the creation of treatments and therapeutics in earnest. I have worked for several major pharmaceutical companies, focusing on research, business, venture creation, and investment in the U.S. During this time, I also serve as a faculty member of graduate program at the university.
-
Aging & Rejuvenation Research Series Vol.4: The Nine Hallmarks of Stem Cell Aging
[Review] A Landmark Overview on Stem Cell Aging, Cell Stem Cell 2025 Introduction As we age, one of the most fundamental biological changes is the decline in stem cell function. Stem cells are essential for maintaining tissue homeostasis... -
Drug Discovery News
BPI Technology Advances Targeted Protein Degradation — A Site-Specific Strategy to Accelerate Drug Discovery Introduction Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, offering a means to ... -
Treatment News
A New Era in Flu Prevention? — CD388 Shows One-Shot Seasonal Protection Introduction Flu prevention has long relied on seasonal vaccines, but a new innovation may challenge that paradigm. CD388, a long-acting antiviral developed by Cidar... -
Aging, Rejuvenation and Regeneration Series Vol. 3: Is the Brain the Master Regulator of Aging?
New Hypothesis Links Stress, the Brain, and Systemic Aging In the June 2025 issue of Nature (Vol.642), researchers from Columbia University led by Dr. Martin Picard proposed that senescent cells—those associated with aging—may consume do... -
How Did Japanese Pharma Choose and Compete Globally? — A 2015–2025 Strategic Overview
Introduction Over the past decade, major Japanese pharmaceutical companies have undergone significant evolution amidst global competition. Daiichi Sankyo, Takeda, Otsuka, and Astellas have each leveraged their strengths to enhance compet... -
What Did Big Pharma Bet On? — Technology and Therapeutic Trends Seen Through 2015–2025 M&A and Partnerships
Introduction Between 2015 and 2025, global pharmaceutical giants have expanded into innovative therapeutic areas and pursued internalization or adoption of novel technologies. Based on the strategic movements of 22 companies, this articl... -
Rare & Pediatric Disease News Vol.4: Organoid-Based Discovery for UBA5-Linked Pediatric Epileptic Encephalopathy
Screenshot Human Brain Organoids Reveal Therapeutic Potential for Rare Pediatric Epilepsy In June 2025, a research team led by Dr. Heather Mefford at St. Jude Children’s Research Hospital reported a groundbreaking study using human brain... -
Oncology Drug Approval News Flash: Sunvozertinib (Zegfrovy) Approved for EGFR Exon20 Insertion-Positive NSCLC
[FDA Accelerated Approval] New Oral TKI for Advanced NSCLC with EGFR Exon20 Insertions On July 2, 2025, the FDA granted accelerated approval to Sunvozertinib (brand name: Zegfrovy) for the treatment of adult patients with locally advance... -
Oncology Drug Approval News Flash: FDA Grants Accelerated Approval to Lynozyfic (linvoseltamab) for Relapsed/Refractory Multiple Myeloma
[FDA Approval] BCMA/CD3 Bispecific Antibody Approved on July 2, 2025 On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab (brand name: Lynozyfic) for the treatment of adults with rela... -
[Science News] Cancer Discovery Perspective: Restoring Tumor Suppressor Function of Mutant p53 via Small Molecules
A study published in the June 2025 issue of Cancer Discovery reports a novel small-molecule strategy to restore the tumor suppressor function of mutant p53 proteins. This work was also featured in a companion Perspective article, highlig... -
Biotech Investment News: Major Pharmaceutical Deals of Astellas Pharma (2015–2025)
Strategic Review: Investing in Marketed Products and Next-Gen Modalities Astellas Pharma has executed a series of acquisitions and collaborations from 2015 to 2025 focused on immuno-oncology, ophthalmology, neurology, and gene therapy. K... -
Biotech Investment News: Key Pharmaceutical Deals of Otsuka (2015–2025)
Strategic Overview: Otsuka’s Global Expansion in CNS and Rare Diseases Otsuka Pharmaceutical has focused heavily on the central nervous system (CNS), leveraging U.S.-centered M&A and partnerships to expand its product pipeline. In re... -
Biotech Investment News: Major Pharmaceutical Deals of Daiichi Sankyo (2015–2025)
Strategic Review: Global Expansion through ADC-Focused Oncology Partnerships Daiichi Sankyo has built a strong global presence through its antibody-drug conjugate (ADC) platform. While previous partnerships with AstraZeneca and Seagen we... -
Biotech Investment News: Takeda’s 10-Year Deal Summary & 2025 Update (2015–2025)
Strategic Review: Rare Disease, GI, Vaccines, and Innovation Takeda has transformed itself into a global biopharma leader through acquisitions such as Nycomed in 2011 (expanding GI/respiratory reach in Europe), Shire in 2018 (rare diseas... -
FDA Treatment News: FDA Eliminates REMS for Autologous CAR-T Cell Therapies
[Regulatory Update] FDA Removes REMS Requirements for Approved CAR-T Therapies In June 2025, the U.S. Food and Drug Administration (FDA) officially eliminated Risk Evaluation and Mitigation Strategies (REMS) requirements for autologous c... -
Biotech Investment News: Vertex’s Major Biotech Deals (2015–2025)
Strategic Review: From Cystic Fibrosis to Gene Editing and Regenerative Medicine Vertex Pharmaceuticals has leveraged its dominance in cystic fibrosis (CF) treatment to expand into gene editing, regenerative medicine, pain management, an... -
Biotech Investment News: Regeneron’s Major Biotech Deals (2015–2025)
Strategic Review: Antibody Innovation Meets Gene Editing and RNA Technology Regeneron Pharmaceuticals has leveraged its VelociSuite antibody platform to become a leader in ophthalmology, oncology, and immunology. Over the last decade, it... -
Biotech Investment News: Novo Nordisk’s Major Deals from 2015 to 2025
Strategic Overview: Expanding from Diabetes to Obesity, RNA, and Cardiometabolic Disease Novo Nordisk, known for its leadership in GLP-1 receptor agonists (Ozempic, Wegovy), has expanded significantly over the past decade. Through acquis... -
Biotech Investment News: Major Gilead Deals Over the Past Decade (2015–2025)
Strategic Review: Shifting from Antivirals to Oncology and Cell Therapy Gilead Sciences, once dominant in the antiviral space—particularly in HIV and hepatitis C—has been facing declining revenue due to patent cliffs. Since 2015, the com... -
Biotech Investment News: Bayer’s Major Biotech Deals (2015–2025)
Strategic Review: Building a Cell and Gene Therapy Pipeline with BlueRock and AskBio Over the past decade, Bayer has transitioned from conventional pharmaceuticals into emerging modalities like gene editing, cell therapies, and regenerat...